Anteris Technologies

Anteris Technologies is an Australian biotechnology and medical-device company whose current identity is associated with structural-heart disease and transcatheter heart-valve technology. Its best-known contemporary development program is DurAVR, a transcatheter aortic-valve system intended for catheter-based treatment of aortic-valve disease. The company’s stated area of interest places it within the structural-heart segment, where device developers seek alternatives or complements to conventional open-heart valve surgery. Publicly available material describes the company’s technology focus but does not, in the supplied references, establish a complete regulatory approval profile, commercial launch timetable, sales record, or current geographic distribution for DurAVR. The company has a longer corporate history than its present name suggests. Its origins trace to Allied Medical, a business spun out of mining company Fortescue in 2005. Allied Medical initially concentrated on medical equipment, including catheters, before expanding into biotechnology. In July 2010 it acquired a 38.6 percent interest in Brisbane-based biotechnology company Coridon for A$3 million, increasing that holding to 55 percent by February 2011. During the same month, Allied Medical agreed to a reverse takeover transaction with listed biotechnology company BioMD. The transaction was completed in June 2011, and the combined business listed on the Australian Securities Exchange as Allied Healthcare Group. The company subsequently developed a regenerative-tissue and medical-device business. In September 2012, Allied Healthcare raised A$10.4 million to support the European launch of CardioCel, a bioengineered tissue patch used in cardiovascular and other surgical applications. In November 2013, the company changed its name to Admedus. The following month, Admedus acquired a manufacturing facility in Malaga, Western Australia, to increase CardioCel production capacity and support additional regenerative-tissue products. This manufacturing capability became an important part of the company’s operating history and later supported production arrangements after the business divested its principal patch products. In October 2019, Admedus sold its CardioCel and VascuCel patch businesses to United States-based LeMaitre Vascular. The transaction included A$22.8 million in upfront consideration, deferred payments of A$1 million at 12 and 36 months, and potential earn-out payments of up to A$11.4 million. Admedus retained the right to manufacture the products at its Malaga facility for LeMaitre for three years after the transaction. The divestment marked a significant portfolio shift away from the company’s earlier regenerative-tissue patch operations and toward its structural-heart technology strategy. In May 2020, Admedus changed its name to Anteris Technologies. Under the Anteris name, the company has been publicly associated primarily with heart-valve development, particularly transcatheter aortic-valve replacement. The available reference material is not sufficient to confirm the full sequence of later clinical, regulatory, financing, leadership, or commercialization events. Consequently, this dossier records the company’s documented corporate transitions and principal product programs without adding unverified claims about approval status, revenue, market share, management, or current headquarters.

Anteris Technologies developed from a sequence of Australian medical and biotechnology businesses. Its earliest identified predecessor was Allied Medical, a company spun out of Fortescue in 2005. Allied Medical initially sold medical equipment, including catheters. In July 2010, it entered biotechnology by purchasing a 38.6 percent interest in Brisbane-based Coridon for A$3 million. The holding rose to 55 percent by February 2011. Also in February 2011, Allied Medical agreed to a reverse takeover with BioMD, an already listed biotechnology company. Completion in June 2011 created Allied Healthcare Group, which listed on the Australian Securities Exchange. The combined company expanded its activities in medical devices, biotechnology and regenerative tissue products. In September 2012, Allied raised A$10.4 million to support the European launch of CardioCel. CardioCel was part of the company’s regenerative-tissue and cardiovascular product portfolio. In November 2013, Allied Healthcare changed its corporate name to Admedus. In December of that year, Admedus purchased a manufacturing site in Malaga, Western Australia. The facility was intended to increase CardioCel production and support development and manufacture of further regenerative-tissue products. The company’s portfolio changed materially in October 2019, when Admedus sold its CardioCel and VascuCel patch businesses to LeMaitre Vascular, a United States medical-device company. The agreement provided A$22.8 million in upfront consideration, deferred payments of A$1 million at 12 months and 36 months, and the possibility of up to A$11.4 million in earn-out payments. Admedus retained a manufacturing right for the products at its Malaga facility for the following three years, allowing continuity of supply after the divestment. In May 2020, Admedus adopted the name Anteris Technologies. The current brand is publicly associated with structural-heart disease, particularly transcatheter aortic-valve replacement and the DurAVR valve system. The supplied sources do not provide enough information to establish a complete account of subsequent clinical trials, regulatory clearances, product commercialization, headquarters, executives, or financial performance. Those areas therefore remain unconfirmed in this dossier.

• 2020

  Admedus becomes Anteris Technologies

  [1]Anteris Technologiesen.wikipedia.org

  The company changed its name to Anteris Technologies.

• 2019

  CardioCel and VascuCel businesses divested

  [1]Anteris Technologiesen.wikipedia.org

  Admedus sold the two patch businesses to LeMaitre Vascular while retaining a temporary manufacturing arrangement.

• 2013

  Name changed to Admedus and Malaga facility acquired

  [1]Anteris Technologiesen.wikipedia.org

  The company adopted the Admedus name and acquired a Malaga manufacturing site for CardioCel and other regenerative-tissue products.

• 2012

  Funding for European CardioCel launch

  [1]Anteris Technologiesen.wikipedia.org

  Allied raised A$10.4 million to support CardioCel commercialization in Europe.

• 2011

  BioMD reverse takeover completed

  [1]Anteris Technologiesen.wikipedia.org

  The Allied Medical and BioMD transaction was completed, creating Allied Healthcare Group and an ASX-listed combined company.

• 2010

  Entry into biotechnology

  [1]Anteris Technologiesen.wikipedia.org

  Allied Medical acquired a 38.6 percent stake in Coridon for A$3 million, beginning its expansion into biotechnology.

• 2005

  Allied Medical is spun out of Fortescue

  [1]Anteris Technologiesen.wikipedia.org

  Allied Medical was established as a Fortescue spin-out focused initially on medical equipment such as catheters.

Developer of structural-heart and transcatheter valve technologies, with historical operations in regenerative cardiovascular tissue products.

• Transcatheter aortic-valve system

  DurAVR

  DurAVR is Anteris Technologies’ principal publicly identified structural-heart product program. It is a transcatheter aortic-valve system intended for catheter-based treatment of aortic-valve disease. The supplied reference material does not establish its approval status, commercial availability, launch date, or distribution by market.

• Regenerative cardiovascular tissue patch · 2012

  CardioCel

  CardioCel was a major regenerative-tissue product in the company’s historical portfolio. Allied Healthcare raised funds in 2012 to support its European launch, and Admedus later expanded manufacturing capacity through its Malaga facility. The CardioCel business was sold to LeMaitre Vascular in 2019, with Admedus retaining a temporary manufacturing right.

• Vascular tissue patch

  VascuCel

  VascuCel was part of the vascular and regenerative-tissue patch portfolio operated under Admedus. The business was sold together with CardioCel to LeMaitre Vascular in 2019. The supplied sources do not provide a detailed product specification or independent commercialization history.

• 2020

  Rebranding from Admedus to Anteris TechnologiesStrategy

  Background

  Following the divestment of the CardioCel and VascuCel businesses, the company adopted a new name associated with its subsequent structural-heart focus.

  Action taken

  Admedus changed its corporate name to Anteris Technologies.

  Aftermath

  The Anteris identity became associated with transcatheter aortic-valve and other structural-heart technologies, including the DurAVR program.

  Source

• 2019

  Divestment of CardioCel and VascuCelM&A

  Background

  Admedus agreed to sell its CardioCel and VascuCel patch businesses to LeMaitre Vascular as the company’s portfolio shifted toward other biotechnology and structural-heart opportunities.

  Action taken

  The transaction transferred the two patch businesses to LeMaitre Vascular. Admedus received A$22.8 million upfront, with additional deferred and potential earn-out consideration, and retained a three-year manufacturing right at its Malaga facility.

  Aftermath

  The transaction reduced Admedus’s direct ownership of the patch businesses while preserving a temporary manufacturing role and preceded the company’s 2020 rebranding as Anteris Technologies.

  Transaction consideration. A$22.8 million upfront; A$1 million deferred at 12 months and 36 months; up to A$11.4 million in earn-outs (2019 transaction)

  Source

• 2022.03.03

  Reported2022.03.03

  Anteris Technologies secures US$20 million investment[2]Anteris Technologies获得2000万美元投资proactiveinvestors.com.au

  Anteris Technologies secured a US$20 million investment from Perceptive Advisors, providing funding as the company works to bring its heart valve technology to market.

• 2021.10.12

  Reported2021.10.12

  Anteris partners with IQVIA and CRF for FDA feasibility study[3]Anteris 与 IQVIA 和 CRF 合作开展 FDA 可行性研究proactiveinvestors.com.au

  Anteris Technologies partnered with IQVIA and the Cardiovascular Research Foundation to help conduct an FDA early feasibility study of its DurAVR THV System.

Read more

1. 1Anteris Technologiesen.wikipedia.org
2. 2Anteris Technologies获得2000万美元投资proactiveinvestors.com.au
3. 3Anteris 与 IQVIA 和 CRF 合作开展 FDA 可行性研究proactiveinvestors.com.au